## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-5.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.02)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA**
- Source: Business Wire | 20251207T140841 | Bullish | Relevance: 99%
- The U.S. FDA has granted Breakthrough Therapy designation to Incyte's INCA033989, a first-in-class monoclonal antibody targeting mutant calreticulin (mutCALR) for patients with essential thrombocythemia (ET) harboring a Type 1 CALR mutation who are resistant or intolerant to previous treatments. This designation aims to expedite the development of INCA033989, with a Phase 3 program planned for mid-2026 to evaluate its efficacy in ET patients with all CALR mutation types. Updated safety and efficacy data will be presented at the 2025 ASH Annual Meeting, highlighting the potential of this novel therapy for patients with limited options.

**2. Incyte stock holds Market Perform rating at Citizens on CALR therapy lead**
- Source: Investing.com | 20251209T112451 | Bullish | Relevance: 99%
-  Citizens maintained its Market Perform rating on Incyte (NASDAQ:INCY) due to its first-mover advantage in CALR-mutant myeloproliferative neoplasms (MPNs) therapy with its '989 therapy. The company has seen significant momentum, with shares up 40% year-to-date, and positive revisions to earnings expectations from 13 analysts. Despite increasing competition, Incyte is considered the leader, though continued differentiation will be crucial.

**3. Mizuho upgrades Incyte stock rating to Outperform on promising ASH data**
- Source: Investing.com | 20251208T111124 | Bullish | Relevance: 98%
-  Mizuho upgraded Incyte (NASDAQ:INCY) to Outperform from Neutral, raising its price target to $121.00 from $90.00 following promising clinical data presented at the American Society of Hematology (ASH) annual meeting. The upgrade was driven by Incyte's 989 (mutCALR) therapy for myelofibrosis, which showed strong early dose escalation data, and the potential of its pipeline to offset the upcoming loss of exclusivity for Jakafi. Other recent positive developments for Incyte include strong Q3 performance, a raised guidance, and an exclusive option to acquire Prelude Therapeutics’ JAK2V617F inhibitor program.

**4. Incyte (NASDAQ:INCY) Stock Rating Upgraded by Mizuho**
- Source: MarketBeat | 20251209T133335 | Bullish | Relevance: 98%
-  Mizuho has upgraded Incyte (NASDAQ:INCY) from a "neutral" to an "outperform" rating, setting a new price objective of $121.00, suggesting a potential upside of 25.13%. Other analysts have also adjusted their ratings and price targets, with the stock currently having a consensus "Hold" rating and an average price target of $99.07. Incyte recently reported strong quarterly earnings, beating consensus estimates for both EPS and revenue.

**5. Incyte (NASDAQ: INCY) secures FDA Breakthrough tag, eyes 2026 Phase 3 ET program**
- Source: Stock Titan | 20251207T143302 | Bullish | Relevance: 98%
-  Incyte's first-in-class monoclonal antibody, INCA033989, has received FDA Breakthrough Therapy designation for treating essential thrombocythemia (ET) patients with Type 1 CALR mutations resistant to current therapies. This designation paves the way for expedited development due to the drug's potential to significantly improve treatment options, with a Phase 3 program expected to begin in mid-2026. Updated safety and efficacy data will be presented at the 2025 ASH Annual Meeting.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 12.4 |
| Current P/E | 13.9 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -4.6% to -9.7% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 13.7pp (needs >4.0% for momentum thesis). AM_20 at -7.7% indicates price below own 20MA trend. Underperforming sector by 5.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-1.47), momentum weakening. Elevated volume (1.4x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -9.65% (CS: 3) | Weak |
| RSI_14 | 38.0 | Neutral |
| MACD Histogram | -1.47 | Bearish |
| vs SMA20 | 0.923x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.239x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $95.16
- **Stop Loss:** $88.02 (7.5% risk)
- **Target:** $109.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $3,996.72
- **Portfolio %:** 4.00%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*